ecancerHub - A New Approach to Cancer Communication
eurocancercoms has announced the launch of ecancerHub - a new, open-access, integrated approach to providing the whole cancer community - patients, doctors, researchers and policymakers - with high quality and trustworthy information. Integrating the best of social media technology into one unique platform, ecancerHub enables patients, healthcare professionals and researchers to interact, connect and share. They have the opportunity to discuss, debate, generate new ideas, gather opinions and build knowledge not only within their own groups, but also cross-community.
Read more ...
Based on the recommendations of the IMI Research Agenda, the IMI Governing Board has approved the IMI Annual Implementation Plan 2011, including the Scientific Priorities 2011. These priorities have been incorporated into the IMI 4th Call Topics. These priorities have been incorporated into the IMI 4th Call Topics. Applicants intending to submit an Expression of Interest (EoI) in response to the IMI 4th Call should read the Guide for Applicants, the Call Topics, the Rules for Participation, the Rules for Submission, Evaluation and Selection of EoIs and FPPs, the IMI IPR rules and the IMI JU model Grant Agreement.
Read more ...
VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression
VTU Technology, a leading contract research and development company providing services for the fast-track generation of high-performance industrial protein expression strains and processes for the biopharmaceutical and other protein industries announces the launch of their 2nd generation AOX1 promoter variants allowing for methanol-free protein expression in Pichia pastoris.
Read more ...
UCB launched Research Alliance with Harvard University
UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony in Boston in the presence of his Royal Highness Prince Philippe of Belgium. The Alliance creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway.
Read more ...
New Hope in Fight against the Flu
Pharmacelsus GmbH announced its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the
European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.
Read more ...
The VPHI Institute is Fully Operational
The Virtual Physiological Human Institute for Integrative Biomedical Research, in short VPH Institute, was recently established as an international non-profit organisation incorporated in Belgium and it is now ready to operate and to start the membership campaign. The mission of the VPH Institute is to ensure that the Virtual Physiological Human is fully realised, universally adopted, and effectively used both in research and clinic. In spite of the human need to reduce to parts in order to understand, life is the result of an intricate systemic interaction between very many processes occurring at radically different spatial and temporal scales.
Read more ...
Several methods for early diagnosis of Alzheimer's disease developed by European scientists
European scientists have taken several significant steps to enable earlier diagnosis of Alzheimer's disease in PredictAD, an EU-funded project. The scientists have developed new approaches for measuring biomarkers for diagnostics and a novel system for integrating the information systematically. The system provides an objective method for measuring the state of the patient.
Read more ...